Why Isotretinoin Is Worth the Hassle
Buchi Neita, PA-C, opens the episode by acknowledging what many dermatology APPs already feel: isotretinoin is one of the most impactful medications in dermatology, but prescribing it can be a pain in the neck. She notes there is a whole camp of APPs and dermatologists who simply throw up their hands and refuse to prescribe it because of the hoops involved. Neither she nor Miranti thinks that is the right call.
Miranti, the episode's acne expert with 23-plus years of prescribing experience, frames isotretinoin as a life-changing medication. She reminds listeners that PA school typically doesn’t teach this in depth, and that most clinicians learn practical tips for scheduling, documentation, and management along the way.
On mechanism, Miranti explains that isotretinoin is a synthetic derivative of vitamin A—not, as she tells patients, some toxic chemical—that induces apoptosis in sebaceous and meibomian gland cells, physically reducing sebum production. She points out that only three medications reduce sebum production: isotretinoin, spironolactone, and clascoterone. Because it destroys the sebaceous gland, it addresses all four pillars of acne pathogenesis and drives the long-term results clinicians see. She reassures patients that they often regain some sebaceous activity later, but their skin is truly changed for the better.
Build Protocols and Pick the Right Pharmacy
Neita flags documentation as one of her biggest barriers — the piece that earns eye rolls from her MAs at 4:30 in the afternoon. Miranti's answer is protocols, both in the EMR and in the scheduling system. She uses a registration protocol for females, an initiation protocol, and a follow-up protocol, and reminds APPs that the FDA only allows 30 days of medication at a time, meaning these patients are seen every four weeks. She stresses that MAs need to adjust the isotretinoin monitoring button to the correct month so the system calculates the cumulative dose, and that they should add patient-specific details—angular cheilitis, dry skin, hypertriglyceridemia—to the protocol for each visit. Neita adds that using the right chief complaint in the EMR pulls up a thorough checklist that makes the visit easier.
On pharmacies, both hosts have moved away from big-box options. Miranti puts it bluntly: friends do not let friends use big-box pharmacies for isotretinoin. She wants next-day delivery from a specialty pharmacy, so iPLEDGE windows do not close — patients must have the drug in hand within seven days of confirmation. She also emphasizes continuity, keeping patients on the same generic because different products have different absorptive potential. New prescribers, she notes, must become iPLEDGE prescribers, understand the specific time windows, and can register MAs, RNs, or other providers as delegates or designees for coverage. As Neita observes, when something goes wrong in iPLEDGE, it is always the prescriber's fault.
Choosing Candidates and Counseling Patients
Miranti reviews the AAD's 2024 acne guidelines, which broadened the picture of an isotretinoin candidate beyond severe, cystic, or scarring acne. The guidelines specifically mention scarring — including persistent hyperpigmentation that is especially bothersome for patients with darker skin tones — and psychosocial burden. She and Neita both push back on reserving the drug as a last resort, citing antibiotic stewardship, and encourage APPs to at least offer it to moderate-to-severe patients with psychosocial burden, scarring, or a trajectory toward a bad outcome. Miranti also relays that the new guidelines recommend monitoring only LFTs and lipids, and note that population-based studies have not identified an increased risk of neuropsychiatric conditions or inflammatory bowel disease. Pregnancy prevention remains mandatory for persons of pregnancy potential.
Counseling, Miranti says, is a major hack in itself. Patients arrive with misconceptions — often from a friend, cousin, or neighbor — and clinicians need to counsel with confidence. The top four adverse events all involve dryness (lips, skin, eyes), with photosensitivity, initial worsening or purging, and musculoskeletal complaints rounding out the list. She recommends a tangible do's-and-don'ts list, lipid- or ceramide-based moisturizers, non-comedogenic cleansers without salicylic acid, glycolics, or benzoyl peroxide, and ibuprofen rather than acetaminophen for aches. Because isotretinoin is metabolized by the liver, she counsels no alcohol and no Tylenol, and notes publications supporting omega-3 supplements for dryness and over-the-counter antihistamines like loratadine or cetirizine to reduce initial purging. Since vitamin A is fat-soluble, she tells patients to dose with a healthy fat — half an avocado, eggs, a scoop of peanut butter, or even, she jokes, their Chick-fil-A fries.
Dosing to Clearance and the Post-Course Plan
Miranti favors starting low and going slow — typically 0.5 mg/kg once daily in the morning with dietary fat — checking LFTs and lipids at the end of the first month, then increasing to 1 mg/kg if labs look fine. This approach reduces the risk of pseudo acne fulminans, especially in younger patients with inflammatory or cystic acne. She looks for three boxes before stopping: at least a 20-week minimum, a cumulative dose of 120–150 mg/kg, and complete clinical clearance for at least one to two months. She would rather add a month, even at a trimmed-down dose, than risk an unnecessary repeat course later. Both hosts caution against being stuck in a rigid five-month course.
On the microdosing trend, Miranti considers it a reasonable option for some male patients but flags that it becomes burdensome for patients of pregnancy potential, who must maintain all iPLEDGE rules while it takes far longer to reach the target cumulative dose. Her rule of thumb: get patients clear at a traditional dose first, then consider microdosing afterward. Finally, she does not leave patients high and dry after their course. Her protocol is to start a topical retinoid of choice — even the night of the last isotretinoin dose — to prevent future breakouts as sebaceous activity returns and to keep working on post-inflammatory hyperpigmentation and scarring, ideally choosing a retinoid with clinical data behind it.